Esperion Therapeutics, Inc.
ESPR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.11 | -0.02 | 0.19 |
| FCF Yield | -0.82% | -16.22% | -8.01% | -8.12% |
| EV / EBITDA | -32.66 | 44.98 | -22.17 | -119.76 |
| Quality | ||||
| ROIC | -199.70% | 8.73% | -19.99% | -2.85% |
| Gross Margin | -109.08% | 74.98% | 51.48% | 62.91% |
| Cash Conversion Ratio | 0.14 | 2.47 | 0.56 | 1.64 |
| Growth | ||||
| Revenue 3-Year CAGR | 43.46% | 45.02% | 47.45% | 63.90% |
| Free Cash Flow Growth | 86.36% | -38.86% | 35.26% | 1.52% |
| Safety | ||||
| Net Debt / EBITDA | -3.31 | 32.63 | -8.72 | -31.39 |
| Interest Coverage | 0.10 | 0.73 | -1.14 | -0.27 |
| Efficiency | ||||
| Inventory Turnover | 0.48 | 0.18 | 0.32 | 0.27 |
| Cash Conversion Cycle | 309.97 | 291.35 | 190.56 | 254.79 |